The British Journal of Cardiology

This site is intended for UK healthcare professionals

 
BJC_tv_logo_white
Sign in

Supported

BEACON series – Episode 1: Primary prevention of CVD – QRISK® <10%

This interactive BEACON session explores the management of younger patients at high lifetime cardiovascular risk whose QRISK® scores may underestimate their true risk. The faculty will examine how to identify patients who would benefit from earlier intervention, interpret lifetime versus 10-year cardiovascular risk, and optimise lipid-lowering and cardiovascular risk reduction strategies in line with current evidence and guidelines.

Funding for the filming, production and publishing for this video was provided by A. Menarini Farmaceutica Internazionale SRL. Menarini has had no input into the video's content or hosting.

BEACON series – Episode 2: Secondary prevention post-MI and peripheral artery disease

This interactive BEACON session explores the optimisation of secondary cardiovascular prevention in patients with established atherosclerotic cardiovascular disease. Herein, the faculty will examine how to identify and address residual cardiovascular risk, optimise lipid-lowering therapy beyond statins, and implement evidence-based strategies to achieve recommended LDL-C targets.

Funding for the filming, production and publishing for this video was provided by A. Menarini Farmaceutica Internazionale SRL. Menarini has had no input into the video's content or hosting.

BEACON series – Episode 3: CVD risk management in type 2 diabetes

In this interactive BEACON session, the faculty explore the management of cardiovascular risk in people with type 2 diabetes. They examine how to optimise lipid-lowering therapy, blood pressure control and glucose management, alongside addressing renal risk and implementing evidence-based interventions to reduce long-term cardiovascular complications.

Funding for the filming, production and publishing for this video was provided by A. Menarini Farmaceutica Internazionale SRL. Menarini has had no input into the video's content or hosting.

BEACON series – Episode 4: Type 2 diabetes and chronic kidney disease

In this interactive BEACON session, the faculty explore the complexities of managing multifactorial cardiometabolic risk in primary care, looking at the fictional case of a 67-year-old man with long-standing type 2 diabetes, CKD stage 3a with rising albuminuria, obesity and multiple modifiable risk factors.

Funding for the filming, production and publishing for this video was provided by A. Menarini Farmaceutica Internazionale SRL. Menarini has had no input into the video's content or hosting.

What to expect when you visit the National Amyloidosis Centre

An educational walkthrough video to share with your patients referred to the National Amyloidosis Centre (NAC), providing an overview of what to expect during their visit. The video describes the range of investigations that may be undertaken at the NAC, and which healthcare professionals patients may meet at their appointment.

Funding for these videos has come from multiple pharmaceutical industry sponsors. Further details of each company’s involvement can be found on the video page.

The National Amyloidosis Centre: A guide for clinicians

This short video outlines the role of the NAC (National Amyloidosis Centre) in managing patients you refer to them with suspected amyloidosis. It highlighting the use of accurate diagnostic testing techniques available at the NAC, including imaging, histology and proteomics, as well as the genetic testing and counselling that provide important components of holistic care.

Funding for these videos has come from multiple pharmaceutical industry sponsors. Further details of each company’s involvement can be found on the video page.

Hiding in plain sight – a case-based overview of amyloidosis

Experts from the National Amyloidosis Centre in London examine three case studies, specifically focusing upon the symptoms that first aroused suspicion, the diagnostic tests that confirmed the condition, and the treatment options available to these patients.

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence.

Amyloidosis: a comprehensive guide for the cardiovascular team

A guide for all members of the cardiovascular and primary care teams on what to look for, and what to do if you suspect amyloidosis: signs and symptoms, diagnostic tests and studies, and the treatment options currently available.

Funding for this video has come from multiple pharmaceutical industry sponsors. Further details of each company’s involvement can be found on the video page.

ESC Congress 2024 highlights – A UK perspective: What’s new in the latest ESC guideline update?

Dr Paul Foley and Prof Terry McCormack share the key changes in the new ESC guidance on atrial fibrillation, hypertension and arterial disease.

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.